Medtronic (MDT) Stock Forecast & Price Target

Compare

6,407 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

MDT Analyst Ratings

Moderate Buy

12 Buy

7 Hold

0 Sell

Based on 19 analysts giving stock ratings to

Medtronic

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

MDT Stock 12 Month Forecast

Average Price Target

$112.93

▲(14.66% Upside)

Based on 19 Wall Street analysts offering 12 month price targets for Medtronic in the last 3 months. The average price target is $112.93 with a high forecast of $125.00 and a low forecast of $100.00. The average price target represents a 14.66% change from the last price of $98.49.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"80":"$80","103":"$103","126":"$126","91.5":"$91.5","114.5":"$114.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":125,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$125.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":112.93,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$112.93</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":100,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$100.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[80,91.5,103,114.5,126],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,102.71,104.42461538461538,106.13923076923076,107.85384615384615,109.56846153846153,111.28307692307692,112.9976923076923,114.71230769230769,116.42692307692307,118.14153846153846,119.85615384615384,121.57076923076923,123.28538461538461,{"y":125,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,102.71,103.49615384615385,104.28230769230768,105.06846153846153,105.85461538461539,106.64076923076922,107.42692307692307,108.21307692307693,108.99923076923078,109.78538461538461,110.57153846153847,111.35769230769232,112.14384615384616,{"y":112.93,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,102.71,102.50153846153846,102.29307692307692,102.08461538461538,101.87615384615384,101.6676923076923,101.45923076923077,101.25076923076922,101.04230769230769,100.83384615384615,100.62538461538462,100.41692307692307,100.20846153846153,{"y":100,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":88.04,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":89.21,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":86.46,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":81.65,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":81.82,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":87.44,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":88.02,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":91.95,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":94.12,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":90.04,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":102.58,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":96.06,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":102.71,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$125.00

Average Price Target$112.93

Lowest Price Target$100.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Richard Newitter

Truist Financial

$107→$103

Hold

4.58%

Upside

Reiterated

02/19/26

Medtronic price target lowered to $103 from $107 at TruistMedtronic price target lowered to $103 from $107 at Truist

Anthony Petrone

Mizuho Securities

$125

Buy

26.92%

Upside

Initiated

02/18/26

Medtronic resumed with an Outperform at MizuhoMedtronic resumed with an Outperform at Mizuho

Joanne Wuensch

Citi

Buy

―

Reiterated

02/18/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Medtronic (NYSE: MDT), Bausch Health Companies (NYSE: BHC) and Insulet (NASDAQ: PODD)

David Rescott

Robert W. Baird

$103→$100

Hold

1.53%

Upside

Reiterated

02/18/26

Medtronic price target lowered to $100 from $103 at BairdMedtronic price target lowered to $100 from $103 at Baird

Larry Biegelsen

Wells Fargo

$114

Buy

15.75%

Upside

Reiterated

02/18/26

Wells Fargo Sticks to Its Buy Rating for Medtronic (MDT)

Lee Hambright

Bernstein

$112

Buy

13.72%

Upside

Reiterated

02/18/26

Analysts Are Bullish on These Healthcare Stocks: Neurosense Therapeutics Ltd. (NRSN), Immunovant (IMVT)

Robbie Marcus

J.P. Morgan

Hold

―

Reiterated

02/17/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: IDEAYA Biosciences (NASDAQ: IDYA) and Medtronic (NYSE: MDT)

Matt Miksic

Barclays

$116→$118

Buy

19.81%

Upside

Reiterated

02/17/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Travis Steed

Bank of America Securities

$115→$110

Buy

11.69%

Upside

Reiterated

02/17/26

Analysts Offer Insights on Healthcare Companies: Medtronic (NYSE: MDT), Elanco Animal Health (NYSE: ELAN) and Werewolf Therapeutics (NASDAQ: HOWL)

Danielle Antalffy

UBS

$104

Hold

5.59%

Upside

Reiterated

02/17/26

Medtronic: Solid Quarter but Limited Growth Visibility Justifies Hold Rating

Josh Jennings

TD Cowen

$119

Buy

20.82%

Upside

Reiterated

02/17/26

Medtronic: Sustained Outperformance and Multi‑Year Growth Runway Driven by Cardiovascular and Robotics Pipelines

Shagun Singh Chadha

RBC Capital

$118

Buy

19.81%

Upside

Reiterated

02/17/26

Analysts Offer Insights on Healthcare Companies: Gilead Sciences (NASDAQ: GILD), Medtronic (NYSE: MDT) and Camurus AB (Other OTC: CAMRF)

Michael Matson

Needham

$121→$120

Buy

21.84%

Upside

Reiterated

02/17/26

Analysts Offer Insights on Healthcare Companies: Krystal Biotech (NASDAQ: KRYS) and Medtronic (NYSE: MDT)

Brandon Vazquez

William Blair

Buy

―

Reiterated

02/17/26

Analysts Conflicted on These Healthcare Names: Masimo (NASDAQ: MASI) and Medtronic (NYSE: MDT)

Ryan Zimmerman

BTIG

Hold

―

Reiterated

02/04/26

Analysts Conflicted on These Healthcare Names: Chugai Pharmaceutical Co (Other OTC: CHGCF), Medtronic (NYSE: MDT) and Insulet (NASDAQ: PODD)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Richard Newitter

Truist Financial

$107→$103

Hold

4.58%

Upside

Reiterated

02/19/26

Medtronic price target lowered to $103 from $107 at TruistMedtronic price target lowered to $103 from $107 at Truist

Anthony Petrone

Mizuho Securities

$125

Buy

26.92%

Upside

Initiated

02/18/26

Medtronic resumed with an Outperform at MizuhoMedtronic resumed with an Outperform at Mizuho

Joanne Wuensch

Citi

Buy

―

Reiterated

02/18/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Medtronic (NYSE: MDT), Bausch Health Companies (NYSE: BHC) and Insulet (NASDAQ: PODD)

David Rescott

Robert W. Baird

$103→$100

Hold

1.53%

Upside

Reiterated

02/18/26

Medtronic price target lowered to $100 from $103 at BairdMedtronic price target lowered to $100 from $103 at Baird

Larry Biegelsen

Wells Fargo

$114

Buy

15.75%

Upside

Reiterated

02/18/26

Wells Fargo Sticks to Its Buy Rating for Medtronic (MDT)

Lee Hambright

Bernstein

$112

Buy

13.72%

Upside

Reiterated

02/18/26

Analysts Are Bullish on These Healthcare Stocks: Neurosense Therapeutics Ltd. (NRSN), Immunovant (IMVT)

Robbie Marcus

J.P. Morgan

Hold

―

Reiterated

02/17/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: IDEAYA Biosciences (NASDAQ: IDYA) and Medtronic (NYSE: MDT)

Matt Miksic

Barclays

$116→$118

Buy

19.81%

Upside

Reiterated

02/17/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Travis Steed

Bank of America Securities

$115→$110

Buy

11.69%

Upside

Reiterated

02/17/26

Analysts Offer Insights on Healthcare Companies: Medtronic (NYSE: MDT), Elanco Animal Health (NYSE: ELAN) and Werewolf Therapeutics (NASDAQ: HOWL)

Danielle Antalffy

UBS

$104

Hold

5.59%

Upside

Reiterated

02/17/26

Medtronic: Solid Quarter but Limited Growth Visibility Justifies Hold Rating

Josh Jennings

TD Cowen

$119

Buy

20.82%

Upside

Reiterated

02/17/26

Medtronic: Sustained Outperformance and Multi‑Year Growth Runway Driven by Cardiovascular and Robotics Pipelines

Shagun Singh Chadha

RBC Capital

$118

Buy

19.81%

Upside

Reiterated

02/17/26

Analysts Offer Insights on Healthcare Companies: Gilead Sciences (NASDAQ: GILD), Medtronic (NYSE: MDT) and Camurus AB (Other OTC: CAMRF)

Michael Matson

Needham

$121→$120

Buy

21.84%

Upside

Reiterated

02/17/26

Analysts Offer Insights on Healthcare Companies: Krystal Biotech (NASDAQ: KRYS) and Medtronic (NYSE: MDT)

Brandon Vazquez

William Blair

Buy

―

Reiterated

02/17/26

Analysts Conflicted on These Healthcare Names: Masimo (NASDAQ: MASI) and Medtronic (NYSE: MDT)

Ryan Zimmerman

BTIG

Hold

―

Reiterated

02/04/26

Analysts Conflicted on These Healthcare Names: Chugai Pharmaceutical Co (Other OTC: CHGCF), Medtronic (NYSE: MDT) and Insulet (NASDAQ: PODD)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Medtronic

3 Months

xxx

Success Rate

17/22 ratings generated profit

Average Return

+4.58%

a xxx

rating ―

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 77.27% of your transactions generating a profit, with an average return of +4.58% per trade.

1 Year

Josh JenningsTD Cowen

Success Rate

24/25 ratings generated profit

Average Return

+11.58%

a rating ―

Copying Josh Jennings's trades and holding each position for 1 Year would result in 96.00% of your transactions generating a profit, with an average return of +11.58% per trade.

2 Years

xxx

Success Rate

24/25 ratings generated profit

Average Return

+18.46%

a xxx

rating ―

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 96.00% of your transactions generating a profit, with an average return of +18.46% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

MDT Analyst Recommendation Trends

Rating

Oct 25

Nov 25

Dec 25

Jan 26

Feb 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, MDT has received 30 Buy Ratings, 18 Hold Ratings, and 0 Sell Ratings. MDT average Analyst price target in the past 3 months is 112.93.

Each month's total comprises the sum of three months' worth of ratings.

MDT Financial Forecast

MDT Earnings Forecast

Next quarter’s earnings estimate for MDT is $1.67 with a range of $1.66 to $1.70. The previous quarter’s EPS was $1.36. MDT beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year MDT has Performed in-line its overall industry.

MDT Sales Forecast

Next quarter’s sales forecast for MDT is $9.65B with a range of $9.61B to $9.71B. The previous quarter’s sales results were $9.02B. MDT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year MDT has Performed in-line its overall industry.

MDT Stock Forecast FAQ

What is MDT’s average 12-month price target, according to analysts?

Based on analyst ratings, Medtronic’s 12-month average price target is 112.93.

What is MDT’s upside potential, based on the analysts’ average price target?

Medtronic has 14.66% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is MDT a Buy, Sell or Hold?

Medtronic has a consensus rating of Moderate Buy which is based on 12 buy ratings, 7 hold ratings and 0 sell ratings.

What is Medtronic’s price target?

The average price target for Medtronic is 112.93. This is based on 19 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $125.00 ,the lowest forecast is $100.00. The average price target represents 14.66% Increase from the current price of $98.49.

What do analysts say about Medtronic?

Medtronic’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 19 Wall Streets Analysts.

How can I buy shares of MDT?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Medtronic (MDT) Stock Forecast & Price Target

MDT Analyst Ratings

MDT Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Medtronic

MDT Analyst Recommendation Trends

MDT Financial Forecast

MDT Earnings Forecast

MDT Sales Forecast

MDT Stock Forecast FAQ

Detailed List of Analyst Forecasts